Cognition Therapeutics (CGTX) News Today $2.17 -0.19 (-8.05%) Closing price 04:00 PM EasternExtended Trading$2.22 +0.04 (+2.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Wall Street ZenSeptember 8, 2025 | marketbeat.comQ3 EPS Forecast for Cognition Therapeutics Raised by AnalystSeptember 7, 2025 | marketbeat.comCognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comQ3 EPS Estimate for Cognition Therapeutics Raised by AnalystSeptember 7, 2025 | americanbankingnews.comThese Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025September 3, 2025 | msn.comCognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollmentSeptember 3, 2025 | msn.comCognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support ...September 3, 2025 | markets.businessinsider.comCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment TargetSeptember 3, 2025 | markets.businessinsider.comCognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease TreatmentSeptember 3, 2025 | quiverquant.comQCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment TargetSeptember 3, 2025 | globenewswire.comCognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)September 2, 2025 | globenewswire.comCognition Therapeutics stock falls after $30 million direct offeringAugust 28, 2025 | in.investing.comCognition Therapeutics launches $30M share offeringAugust 28, 2025 | msn.comCognition Therapeutics, Inc. Announces $30 Million Registered Direct Offering to Fund Phase 3 Programs for Neurodegenerative DisordersAugust 27, 2025 | quiverquant.comQCognition Therapeutics Announces $30 Million Registered Direct Offering of Common StockAugust 27, 2025 | globenewswire.comCognition Therapeutics Regains Nasdaq ComplianceAugust 27, 2025 | msn.comCognition Therapeutics regains compliance with NasdaqAugust 26, 2025 | msn.comCognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" RatingAugust 26, 2025 | seekingalpha.comCognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 26, 2025 | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest UpdateAugust 22, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for CGTX FY2025 Earnings?August 16, 2025 | marketbeat.comCognition Therapeutics Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comCognition Therapeutics Shares Surge After FDA Confirms Phase 3 Trial DesignAugust 13, 2025 | msn.comCognition Therapeutics confirms aligment with FDA on path for zervimesineAugust 12, 2025 | msn.comCognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's DiseaseAugust 12, 2025 | globenewswire.comCognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical ProgramsAugust 8, 2025 | theglobeandmail.comCognition (CGTX) Q2 Grant Income JumpsAugust 8, 2025 | fool.comCognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s DiseaseJuly 30, 2025 | finance.yahoo.comCognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's DiseaseJuly 29, 2025 | globenewswire.comCognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's DiseaseJuly 21, 2025 | globenewswire.comCognition Therapeutics stock soars after DLB study resultsJuly 16, 2025 | in.investing.comCognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAICJuly 16, 2025 | globenewswire.comCognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study ProgressJuly 11, 2025 | insidermonkey.comCognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's DiseaseJuly 11, 2025 | finanznachrichten.deCognition Therapeutics Shares Jump 75% After FDA Discussion on Alzheimer’s TreatmentJuly 11, 2025 | msn.comCognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesineJuly 11, 2025 | msn.comCognition Therapeutics stock soars after FDA meeting on Alzheimer’s drugJuly 10, 2025 | in.investing.comCognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s DiseaseJuly 10, 2025 | finance.yahoo.comCognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDAJuly 10, 2025 | quiverquant.comQCognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's DiseaseJuly 10, 2025 | globenewswire.comCognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial DataJuly 5, 2025 | benzinga.comCGTX - Cognition Therapeutics Inc Executives - MorningstarJuly 3, 2025 | morningstar.comMCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment TargetJuly 1, 2025 | finance.yahoo.comCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment TargetJuly 1, 2025 | globenewswire.comCognition Therapeutics, Inc. (CGTX) - Yahoo FinanceJune 30, 2025 | finance.yahoo.comCognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)June 25, 2025 | finance.yahoo.comCognition Therapeutics, Inc. Schedules End-of-Phase 2 Meeting with FDA for Alzheimer's Treatment and Files Applications for Breakthrough Status in Dementia with Lewy BodiesJune 25, 2025 | quiverquant.comQCognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)June 25, 2025 | globenewswire.comPhilanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesJune 3, 2025 | finance.yahoo.comPhilanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesJune 3, 2025 | globenewswire.com Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGTX Media Mentions By Week CGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼0.610.93▲Average Medical News Sentiment CGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼62▲CGTX Articles Average Week Get the Latest News and Ratings for CGTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cognition Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Immatics News Today Nurix Therapeutics News Today Oculis News Today Niagen Bioscience News Today Valneva News Today Gyre Therapeutics News Today GH Research News Today Vir Biotechnology News Today Kura Oncology News Today Relay Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts